Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population-based Screening for BRAF V600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Sept 2020

Chu Jenny E, Johnson Benny, Kugathasan Laveniya, Morris Van K, Raghav Kanwal, Swanson Lucas, Lim Howard J, Renouf Daniel J, Gill Sharlene, Wolber Robert, Karsan Aly, Kopetz Scott, Schaeffer David F, Loree Jonathan M

Abstract excerpt

PURPOSE: BRAF V600E mutations portend poor prognosis in metastatic colorectal cancer (mCRC); however, the true prevalence and prognosis are unknown, as unwell patients may not undergo BRAF sequencing. EXPERIMENTAL DESIGN: We reviewed a population-based cohort of 1,898 patients with colorectal cancer that underwent reflexive IHC mismatch repair (MMR) and BRAF V600E testing. Outcomes among IHC-detected BRAF V600E...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Biopsy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to DNA Mismatch Repair

Share to Mass Screening

Share to Molecular Epidemiology

Share to Prevalence

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 32571791
DOI: 10.1158/1078-0432.CCR-20-1024
PMCID: PMC7484131

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population-based Screening for BRAF V600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis.PMID 32571791Read ↗

Improvements in Clinical Outcomes for BRAFV600E -Mutant Metastatic Colorectal Cancer.Semantic proximity Read ↗

Real-world evaluation of treatment patterns and clinical outcomes in patients with BRAF-V600E metastatic colorectal cancer (mCRC) in Canada.Semantic proximity Read ↗

European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer.Semantic proximity Read ↗

Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.Semantic proximity Read ↗

BRAF V600E and Non-V600E Mutations in RAS Wild-Type Metastatic Colorectal Cancer: Prognostic and Therapeutic Insights from a Nationwide, Multicenter, Observational Study (J-BROS)Semantic proximity Read ↗

Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.Semantic proximity Read ↗

Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer.Semantic proximity Read ↗

Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts.Semantic proximity Read ↗

Impact of BRAF Gene Mutation in Nonmetastatic Colorectal Cancer on Disease Progression and Survival Outcomes.Semantic proximity Read ↗

BRAF V600E-Mutated Metastatic Colorectal Cancer: Practical Management in the Post-BREAKWATER Era.Semantic proximity Read ↗

Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States.Semantic proximity Read ↗

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.